Summary: Concern remains that stent thrombosis is a price paid for reducing restenosis, particularly with drug-eluting stents. Fear of clotting dictates procedural protocols, adjunctive medication, and device selection. The authors show here that polymer/drug coatings reduce rather than increase thrombosis early after complex interventions and that stent design and deployment drive thrombogenicity. Thinner devices reduce clot formation, whereas coatings are protective, especially in malapposed and overlap scenarios. Indeed, thin polymer-coated devices exhibit low thrombogenicity even in the most complex settings. By defining clot relative to the flow regimes imposed by struts, our models further explain the lack of consensus in clinical trials that sought to correlate deployment and thrombosis. The authors show here how well-apposed devices create flow separation upstream and downstream of struts and that clot potential tracks with these zones. As struts move off the wall, the flow-separation zones increase and then reduce as flow is restored beneath struts-clotting peaks and falls synchronous with flow alterations. With further displacement, strut-associated disturbances reemerge, eliciting a different pattern of thrombosis. When struts overlap, displaced struts impose a high-risk flow regime, and small changes in strut dimension or stent configuration elicit global changes in flow. Stent thrombosis differs with the nature of flow disruption, and clinical focus on design or deployment alone must give way to a broader context considering their combined impact on flow. Given the inevitable variability in deployment, the choice of optimal design and/or antithrombotic therapies may now be dictated by these patterns of flow disruption.
Conclusions: Contrary to popular perception, drug/polymer coatings do not inherently increase acute stent clotting; they reduce thrombosis. However, strut dimensions and positioning relative to the vessel wall are critical factors in modulating stent thrombogenicity. Optimal stent geometries and surfaces, as demonstrated with thin stent struts, help reduce the potential for thrombosis despite complex stent configurations and variability in deployment. 1 
Impact of Parallel Micro-Engineered Stent Grooves on Endothelial Cell Migration, Proliferation, and Function: An In Vivo Correlation Study of the Healing Response in the Coronary Swine Model
Summary: Restoration of an intact functional endothelium at stented revascularization sites limits thrombosis and arterial wall remodeling. Stent surface biocompatibility influences the endothelialization rate and restoration of implanted stents. Current drugeluting stents inhibit restoration of a functional endothelium. A patterned microgrooved stent surface can increase the rate of surface endothelialization. Increasing the rate of reendothelialization using a microgrooved stent is associated with decreased intimal hyperplasia.
Conclusions: Parallel microgrooves on coronary stent luminal surfaces promote endothelial cell migration and positively influence endothelial cell function, resulting in decreased neointimal formation in the porcine coronary injury model. 2 
Impact of Polymer Formulations on Neointimal Proliferation After Zotarolimus-Eluting Stent With Different Polymers: Insights From the RESOLUTE Trial
Summary: Each component of the drug-eluting stent (DES), platform, drug, and polymer, contributes to acute and mid-term results. In paclitaxel-eluting stents, it has been shown that polymer formulation may play a more important role than drug dose. In the PISCES trial, stents with longer elution (30 days) showed a significantly lower percent neointimal obstruction compared with those with shorter elution (10 days) (8±7% versus 17±13%), suggesting an important role of formulation strategies even for the same drugs. However, this has not been fully evaluated in other DESs. With respect to the zotarolimus-eluting stent (ZES), 3 clinical programs were tested in human clinical trials: Resolute, Endeavor, and ZoMaxx. The Resolute ZES system uses a newly developed biodurable polymer (C10/C19/PVP polymer; BioLinx), which enables longer drug elution and a low-profile thin-strut, cobalt-chromium alloy stent. The purpose of this study was to compare 3 ZESs and evaluate which factor or factors may have the most impact on neointimal suppression. At baseline, vessel, lumen, and peristent plaque VI were not significantly different among the 4 stents. At follow-up, percent neointimal obstruction was significantly lower in the Resolute compared with the Endeavor, ZoMaxx, and Driver trials (Resolute, 3.7±4.0; Endeavor, 17.5±10.1; ZoMaxx, 14.6±8.1; Driver, 29.4±17.2%, Pintima-free frame ratio, suggesting less neointimal coverage, were observed in the Resolute compared with other stent groups. Multiple regression analysis confirmed the biodurable polymer used in Resolute independently correlated with neointimal suppression among 3 ZESs. These findings confirmed that the different polymer formulations significantly affect the relative amount of neointima for ZES.
Conclusions:
The different polymer formulations significantly affect the relative amount of neointima for zotarolimus-eluting stents.
Summary: Drug-eluting stents (DES) have shown success in reducing restenosis; however, late stent thrombosis has emerged as a potential cause of increased morbidity and mortality in a few patients. The authors compared sirolimus-(SES [Cypher] ), zotarolimus-(ZES [Endeavor]), and everolimus-(EES [Xience V]) eluting stents to bare metal stent (BMS) in a rabbit model of atherosclerosis at 28 days to better predict the responses seen in humans. The extent of neointimal area and thickness was significantly less in SES and EES but in between for ZES compared to BMS. Additionally, the number of uncovered stent struts was greater in SES and EES compared to ZES and BMS. ZES was associated with the least fibrin deposition among DES. All DES significantly reduced macrophage infiltration in the neointima compared with BMS. The endothelial coverage by scanning electron microscopy was significantly greater in BMS, ZES, and EES than in SES, but endothelial nitric oxide synthase expression by confocal microscopy was greater in BMS and ZES than in EES and SES; thus, the rabbit atherosclerotic model showed greater reduction of neointimal generation in SES and EES with greater fibrin deposition, but delayed healing was much less in ZES.
The rabbit atherosclerotic model of stenting showed delayed healing and significantly greater reduction of neointima following implantation of SES and EES; however, delayed healing was less in ZES with greater neointima (but less than BMS), endothelial regrowth, and eNOS expression. Summary: The 1-stent bifurcation stenting approach with stenting of the main vessel and optional side branch stenting using drug-eluting stents is the preferred strategy to treat coronary bifurcation lesions. It is unknown whether a successful main vessel stenting procedure should be finalized by a simultaneous kissing balloon dilatation (FKBD). In the present study, 477 patients with successful main vessel stenting were randomized to FKBD versus no FKBD. The 6-month rates of major adverse cardiac events (cardiac death, non-procedure-related index lesion myocardial infarction, target lesion revascularization, or stent thrombosis) were similar and low in the study groups. FKBD reduced angiographic side branch (re)stenosis, especially in patients with true bifurcation lesions. The simple no-FKBD procedures resulted in reduced use of contrast media and shorter procedure and fluoroscopy times. FKBD may be recommended in genuine bifurcation lesions treated with main vessel stenting but may be avoided in bifurcations without side branch stenosis.
Conclusions: MV stenting strategies with and without FKBD were associated with similar clinical outcomes. FKBD reduced angiographic side branch (re)stenosis, especially in patients with true bifurcation lesions. The simple no-FKBD procedures resulted in reduced use of contrast media and shorter procedure and fluoroscopy times. Long-term data on stent thrombosis are needed. The ostial left anterior descending coronary artery (LAD) lesion is an important target for coronary revascularization because its location subtends a large territory of myocardium. However, percutaneous coronary intervention of the ostial LAD often is complicated by involvement of the distal left main coronary artery and potentially compromises the circumflex coronary artery. In this study, the long-term outcomes of sirolimus-eluting stent (SES) implantation for ostial LAD lesions were evaluated. Among 12 824 patients enrolled in the j-Cypher registry, 3-year outcomes were compared between 481 patients with SES-treated ostial LAD lesions and 5369 patients with SES-treated nonostial proximal LAD lesions. Compared with patients with nonostial proximal LAD lesions, patients with ostial LAD lesions had similar incidences of target lesion revascularization and death or myocardial infarction. Among the patients with ostial LAD lesions, those undergoing both main and side branch stenting (n=62) compared with main branch stenting alone (n=419) had a higher risk for target lesion revascularization but a similar risk for death or myocardial infarction. In patients with main branch stenting alone, outcomes after crossover stenting of the circumflex coronary artery (n=225) were not different from those after ostial stenting (n=194) for both target lesion revascularization and death or myocardial infarction. In terms of both safety and efficacy, 3-year outcomes of percutaneous coronary intervention using SES for ostial LAD lesions were comparable to those for nonostial proximal LAD lesions. Crossover stenting with a 1-stent approach might be a reasonable option in treating ostial LAD lesions.
In terms of both safety and efficacy, 3-year outcomes of percutaneous coronary intervention using SES for ostial LAD lesions were comparable to those for nonostial proximal LAD lesions. Crossover stenting with a 1-stent approach might be a reasonable option in treating ostial LAD lesions. Summary: Small-sized 6F guiding catheters are now commonly used as the standard in percutaneous coronary intervention. When treating severely calcified and/or tortuous lesions, however, stent delivery is often difficult with a 6F guiding catheter because of limited backup support. A 4F child guiding catheter that can be inserted into 6F or larger conventional guiding catheters has been recently developed. The use of the 4F child catheter in combination with a 6F motherguiding catheter (the so-called mother-child technique) may improve the delivery of coronary stents in treating complex coronary lesions. In the present study, quantitative measurements using a coronary tree model showed improved backup force and deliverability of the 4-in-6 mother-child guiding systems. The authors demonstrated the successful application of this system in treating complex coronary lesions in which conventional techniques had been unsuccessful for stent delivery.
With the superior trackability of the 4F child catheter and with increased backup support of the mother-child system, the 4F mother-child system provided >90% success rate for lesions in which conventional techniques had failed. The 4F mother-child system may become a viable alternative to conventional techniques in treating complex coronary lesions.
≈12% of patients within 1 year. One fourth of these repeat procedures were staged or planned, generally occurring within the first 1 to 2 months after PCI, and there was significant variability in multivessel disease management between hospitals. The remaining 9% of repeat procedures were unplanned, with half involving TLR and half involving nontarget revascularization, and predictors of these 2 subgroups of repeat revascularization were remarkably different. The low early hazard for stent thrombosis decreases even further after the first month.
Conclusions: Among unselected patients undergoing PCI in the drugeluting stent era, the incidence of repeat revascularization at 1 year is ≈12%. Among unplanned procedures, only half are performed for TLR. To achieve further improvements in PCI outcomes, future efforts should concentrate as much on identifying ischemia-producing lesions and intensifying secondary prevention therapies as on the prevention of restenosis. Summary: Unprotected left main coronary artery disease treated with drug-eluting stents, particularly lesions involving the distal bifurcation, may be complicated by restenosis. Limited data are available on the treatment of drug-eluting stent in-stent restenosis in this high-risk lesion. This study shows that isolated restenosis of the ostium of the left circumflex coronary artery is common and associated with an initial 2-stent strategy compared with a single stent. Whether the higher rates of in-stent restenosis following a 2-stent strategy are due to technique or disease complexity remains to be determined. Drug-eluting stents are more effective than balloon angioplasty for the treatment of unprotected distal left main coronary artery drug-eluting stent instent restenosis.
Conclusions: UDLM restenosis is better treated with DES than with POBA. The rate of recurrent ISR after repeat PCI was high, whereas the rates of MI and death were relatively low. Complex lesions requiring a 2-stent strategy had a higher recurrence rate at the ostial LCX but without an associated increased risk of MI and death. Summary: Controversy persists regarding the correct strategy for the treatment of coronary bifurcation lesions. The authors have carried out a pooled analysis of patient-level data of 913 patients enrolled in 2 randomized trials comparing a simple stenting strategy (stenting of main vessel and provisional treatment of side branch) with a complex strategy (stenting both main vessel and side branch) using drug-eluting stents. Clinical follow-up of these 2 groups to 9 months showed a 10.1% major adverse event rate in the simple group versus a 17.3% major adverse event rate in the complex group. The difference was largely driven by periprocedural myocardial infarction. Procedure duration, contrast volume, and x-ray dose exposure favored the simple group. In addition, a subgroup analysis of more anatomically complicated lesions demonstrated no benefit of a complex strategy. This study, therefore, suggests that the usual strategy for the treatment of bifurcation lesions should be the simple provisional strategy.
Conclusions: For bifurcation lesions, a provisional single-stent approach is superior to systematic dual stenting techniques in terms of safety and efficacy. A complex approach does not appear to be beneficial in more anatomically complicated lesions.
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Impact of Drug-Eluting Stents and Diabetes Mellitus in Patients With Coronary Bifurcation Lesions: A Survey From the Italian Society of Invasive Cardiology
Summary: The authors investigated the relationships between bare metal and drug-eluting (DES) stents according to the presence of diabetes mellitus (DM) among patients undergoing percutaneous coronary intervention of bifurcation lesions. At 3 years, compared with bare metal stents, stenting with DES was associated with lower adjusted risks of major adverse cardiac events, cardiac death, and target lesion revascularization in DM patients. This benefit was not evident among patients without DM. These data suggest the beneficial effects of DES are most notable among patients with more complex types of coronary artery disease.
Conclusions:
In a large observational registry with admitted potential for selection bias and residual confounding, DES in DM patients with coronary bifurcation lesions were associated with improved outcomes in terms of MACE, cardiac death, and repeat revascularization at long-term follow up. These figures were not replicated in non-DM subjects.
11
Complications
Incidence, Risk Factors, and Clinical Sequelae of Angiographic Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation
Summary: The authors have noted abnormal angiographic findings at the site of drug-eluting stent implantation, suggesting contrast staining outside the stent struts that do not fulfill the classic definition of coronary aneurysm. The authors propose a new term, peri-stent contrast staining (PSS), for these abnormal angiographic findings and assess their incidence, risk factors, and clinical sequelae. Peri-stent contrast staining was defined as contrast staining outside the stent contour, extending to ≥20% of the stent diameter. The study population consisted of 3081 lesions (1998 patients) that were treated exclusively with sirolimus-eluting stents and were evaluated by follow-up angiography within 12 months after sirolimus-eluting stent implantation. Late acquired PSS was observed in 58 lesions (1.9%) in 49 patients (2.5%). The independent risk factor of PSS was chronic total occlusion, whereas negative risk factors for PSS were left circumflex coronary artery lesion and in-stent restenosis lesion. Stent fracture was more frequently observed in lesions with PSS than in lesions without PSS (43.1% versus 5.4%, P<0.0001). Cumulative incidence of target-lesion revascularization and definite very late stent thrombosis at 3 years after the index follow-up angiography in the PSS group was higher than that in the non-PSS group (15.0% versus 6.5%, and 8.2% versus 0.2%, respectively). Peri-stent contrast staining found within 12 months after sirolimus-eluting stent implantation seemed to be associated with subsequent target-lesion revascularization and very late stent thrombosis. Although the real incidences and risk factors of very late stent thrombosis and target-lesion revascularization after PSS diagnosis should be evaluated in a larger number of patients with longer follow-up duration, patients with PSS should be followed up very carefully.
Conclusions: Peri-stent contrast staining found within 12 months after sirolimus-eluting stent implantation seemed to be associated with subsequent target-lesion revascularization and very late stent thrombosis.
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inadequate data to establish a single consensus definition for periprocedural MI that is appropriately sensitive for detection of myocardial necrosis while maintaining specificity for potentially clinically meaningful events. The study confirms a marked difference in periprocedural MI rates according to whether historic or universal/ARC MI definitions are used. Use of a more sensitive definition of periprocedural MI based on troponin >3× the diagnostic level for MI increases the sensitivity for diagnosis, but with an event rate of nearly 20% may provide less discrimination for clinically important events. The lack of an association of periprocedural MI by either definition with 2-year mortality supports other studies in low risk patients with otherwise successful procedures.
Conclusions: There was a marked difference in periprocedural MI rates according to protocol or universal/ARC MI definitions. No association was present between periprocedural MI and mortality up to 2 years by either definition.
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Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention: Results From the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry
Summary: Elevated creatine kinase-MB (CK-MB) levels after percutaneous coronary intervention are associated with increased risk of mortality. Although periprocedural myocardial infarction (pMI) is commonly defined as a CK-MB level >3 times the upper limit of normal, use of different laboratory specific assays may translate into variability in relative thresholds, therefore affecting the identification of pMI. The present study identified substantial variability in the upper limit of normal for CK-MB across centers (range, 2.6 to 10.4 ng/mL). A CK-MB level of 30 to 50 ng/mL seems to identify patients with at least a 2-fold increase in 1-year mortality. Use of a threshold CK-MB level to define pMI may decrease variability in pMI detection caused by assay variability and provide additional prognostic information.
Conclusions: Among unselected patients undergoing PCI, there is a graded relationship between CK-MB elevation after PCI and 1-year mortality that is particularly strong for large CK-MB elevations (>30 to 50 ng/mL). Future studies that include pMI as a clinical end point should consider using a core laboratory to assess CK-MB (to ensure consistency) and raising the threshold for defining pMI above current levels (to enhance clinical relevance).
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Incidence and Clinical Impact of Stent Fracture After Everolimus-Eluting Stent Implantation
Summary: Stent fracture after drug-eluting stent implantation has recently become an important concern because of its potential association with in-stent restenosis, target lesion revascularization, and stent thrombosis. The incidence and clinical impact of stent fracture after everolimus-eluting stent remain unclear. Stent fracture after everolimus-eluting stent implantation occurs in 2.9% of lesions.
Conclusions: SF after everolimus-eluting stent implantation occurs in 2.9% of lesions and is associated with higher rate of major adverse cardiac events, driven by higher target lesion revascularization and stent thrombosis. Registry were linked to Medicare inpatient claims to study sex-specific in-hospital and long-term outcomes after an index stent procedure. Additionally, the long-term safety and effectiveness of drug-eluting stents versus bare metal stents were compared in women and men. In the contemporary PCI era, our study shows that elderly women undergoing index PCI remain at higher risk of in-hospital mortality and other complications compared with men. In contrast, long-term outcomes are similar or better in women than in men. The use of drug-eluting stents is associated with a similar benefit in both men and women. Further studies are needed to understand the causative factors for these findings.
Conclusions:
In contemporary coronary stenting, women have a slightly higher procedural risk than men but have better long-term survival. In both sexes, use of a drug-eluting stent is associated with lower long-term likelihood for death, myocardial infarction, and revascularization.
17
Risk of Elective Major Noncardiac Surgery After Coronary Stent Insertion: A Population-Based Study
Summary: For patients with coronary stents, practice guidelines recommend that elective noncardiac surgery be delayed until surgery can be performed safely using antiplatelet therapy with aspirin alone. The suggested delay is 30 to 45 days for bare-metal stents and 1 year for drug-eluting stents. However, these recommendations are largely based on expert opinion and limited data. The authors therefore conducted a population-based cohort study in Ontario, Canada, to describe the risks of major elective noncardiac surgery after stent implantation. After linking population-based administrative databases to a province-wide coronary stent registry, rates of 30-day major adverse cardiac events (mortality, readmission for acute coronary syndrome, repeat coronary revascularization) were measured among patients who underwent major elective noncardiac surgery from 2003 to 2008 after previous stent implantation. The authors found that when the interval between stent implantation and surgery was <45 days, event rates were high for bare-metal (6.7%) and drugeluting (20.0%) stents. When the interval was 45 to 180 days, the event rate for bare-metal stents was 2.6%, which approached that of nonrevascularized individuals with Revised Cardiac Risk Index scores of 1 to 2. Adjusted analyses suggested this event rate increased further if this interval exceeded 180 days. For drug-eluting stents, the event rate was 1.2% once the interval exceeded 180 days, approaching that of nonrevascularized individuals with Revised Cardiac Risk Index scores of 1.
Conclusions:
The earliest optimal time for elective surgery is 46 to 180 days after bare-metal stent implantation or >180 days after drugeluting stent implantation. Summary: The Igaki-Tamai stent is the first-in-man fully biodegradable coronary stent made of poly-l-lactic acid (PLLA). In the present study, there was a high survival rate free of cardiac death (98% at 10 years) demonstrating the long-term safety of this stent.
In the intravascular ultrasound echogenicity analysis, the IgakiTamai stent required 3 years to disappear from human coronary arteries. During the process of biodegradation (1-3 years), target lesion revascularization and target vessel revascularization reached a near plateau, suggesting that the process of PLLA biodegradation does not correlate with increased risk of clinical events. Although the mechanism of vessel healing in a chronic phase may not be the same between Igaki-Tamai stents and bioabsorbable drug-eluting PLLA stents, our study is essential in paving the way for a bioabsorbable drug-eluting PLLA stent, especially from the standpoint of long-term safety.
Conclusions: Acceptable major adverse cardiac events and scaffold thrombosis rates without stent recoil and vessel remodeling suggested the long-term safety of the Igaki-Tamai stent. Summary: There is a scarcity of long-term data from large-scale drug-eluting stent registries with a large enough sample size to evaluate low-frequency events such as stent thrombosis (ST). Fiveyear outcomes were evaluated in 12 812 consecutive patients undergoing sirolimus-eluting stent implantation in the j-Cypher registry. Cumulative incidence of definite ST was low (30 day, 0.3%; 1 year, 0.6%; and 5 years, 1.6%). However, late and very late ST continued to occur without attenuation up to 5 years after sirolimus-eluting stent implantation (0.26%/y). Cumulative incidence of target lesion revascularization within the first year was low (7.3%). However, late target lesion revascularization beyond 1 year also continued to occur without attenuation up to 5 years (2.2%/y). Independent risk factors of ST were completely different according to the timing of ST onset, suggesting the presence of different pathophysiological mechanisms of ST according to the timing of ST onset: acute coronary syndrome and target of proximal left anterior descending coronary artery for early ST; side-branch stenting, diabetes mellitus, and end-stage renal disease with or without hemodialysis for late ST; and current smoking and total stent length >28 mm for very late ST. Independent risk factors of late target lesion revascularization beyond 1 year were generally similar to those risk factors identified for early target lesion revascularization.
Late adverse events such as very late ST and late target lesion revascularization are continuous hazards, lasting at least up to 5 years after implantation of the first-generation drug-eluting stents (sirolimus-eluting stents), which should be the targets for developing improved coronary stents.
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Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention
Summary: Drug-eluting stents for percutaneous coronary intervention decrease the risk of restenosis compared with bare metal stents. However, they are costlier, require prolonged dual antiplatelet therapy, and provide the most benefit in patients at highest risk for restenosis.
To assist physicians in targeting drug-eluting stent use in patients at the highest risk for target vessel revascularization, the authors developed and validated a model to predict target vessel revascularization from a contemporary population-based registry in Massachusetts based on commonly collected clinical and angiographic variables that are obtainable before percutaneous coronary intervention. The ability of the model to discriminate 1-year target vessel revascularization risk among percutaneous coronary intervention patients was significantly better than a simpler model based on the presence of diabetes mellitus, stent length, and stent diameter (c statistic, 0.66 versus 0.60; integrated discrimination index, 0.013; P<0.001). The predicted reduction in target vessel revascularization associated with drug-eluting stents use ranged from as little as 1.2% (95% confidence interval, 0.9-1.6) to 15.9% (95% confidence interval, 13.0-18.4), depending on patient characteristics. Because the predicted benefit associated with drug-eluting stents varies broadly among patients, this predictive model may be used to support the optimal use of drugeluting stents in a prospective fashion and to engage patients in the decision-making process before coronary intervention.
Conclusions: A predictive model using commonly collected variables can identify patients who may derive the greatest benefit in TVR reduction from DES. Whether use of the model improves the safety and cost-effectiveness of DES use should be tested prospectively.
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Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use: Insights From Temporal Analysis of the Multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry
Summary: Although the benefits of drug-eluting stents for reducing restenosis and repeat revascularization after percutaneous coronary intervention are well established, the optimal strategy for their use in clinical practice on both clinical and economic grounds is unknown.
To address this gap in knowledge, the authors used data from a prospective, multicenter percutaneous coronary intervention registry to examine the clinical value and cost-effectiveness of liberal (2004 to 2006) versus selective (2007) drug-eluting stent use strategies in 10 144 patients at 55 US centers. During this time period, the use of drug-eluting stents decreased from 92% to 68% and coincided with an absolute increase of 1% in target lesion revascularization rates. Furthermore, these changes were associated with a reduction in cardiovascular costs of $401 per patient resulting mainly from reduced use of drug-eluting stents in the latter period. One-year rates of death or myocardial infarction were similar in both cohorts. The risk-adjusted incremental cost-effectiveness ratio for the liberal versus selective drug-eluting stent strategy was $16 000 per target lesion revascularization event avoided, $27 000 per repeat revascularization avoided, and $433 000 per quality-adjusted life-year gained.
Conclusions:
In this prospective registry, a temporal reduction in DES use was associated with a small increase in target lesion revascularization and a modest reduction in total cardiovascular costs. These findings suggest that although clinical outcomes are marginally better with unrestricted DES use, this approach represents a relatively inefficient use of healthcare resources relative to several common benchmarks for cost-effective care.
22
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The Long-term Effect of Coronary Stenting on Epicardial and Microvascular Endothelial Function
Summary: Coronary stenting has been linked to epicardial endothelial dysfunction, with a consecutive risk for future events. Although no residual obstructive lesion can be found, a substantial number of patients after stent implantation continue to have recurrent symptoms, which might be attributed to microvascular dysfunction. The study adds knowledge about microcirculatory and epicardial vascular function in patients with stents presenting with chest pain. A long-term worsening of vascular function by drug-eluting stent implantation is not supported.
Conclusions: This study demonstrates that in patients with coronary arteries in which a stent has been placed, coronary microcirculatory and epicardial vascular function are not significantly different from that of an age-and sex-matched population with similar symptoms but nonsignificant coronary artery disease.
23
Outcomes After Coronary Stent Implantation in Patients With Metal Allergy
Summary: Concern exists regarding the safety of coronary stent placement in patients with a history of metal allergy. Earlier studies suggested an increased risk of restenosis in patients who were identified as metal-allergic after stent placement.
Conclusions: A history of metal allergy was not associated with adverse early or late outcomes in this single-center study.
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Incidence and Outcome of Surgical Procedures After Coronary Bare-Metal and Drug-Eluting Stent Implantation: A Report From the CREDO-Kyoto PCI/ CABG Registry Cohort-2
Summary: Surgical procedures after coronary drug-eluting stent implantation, early surgery in particular, carry significant risk for perioperative stent-related ischemic as well as bleeding complications. Surgical procedures were commonly performed after coronary stent implantation in the real clinical practice in Japan (22% at 3 years). Incidences of ischemic and bleeding complications after surgical procedures were acceptably low, with no differences regardless of bare-metal stents and drug-eluting stents use. Perioperative administration of dual-antiplatelet therapy was not associated with lower risk for ischemic events.
Conclusions: Surgical procedures were commonly performed after coronary stent implantation, and the risk of ischemic and bleeding complications in surgical procedures was low. In patients selected to receive DES or BMS, there were no differences in outcomes. Perioperative administration of dual-APT was not associated with lower risk for ischemic events.
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Impact of Incomplete Revascularization on Long-term Mortality After Coronary Stenting
Summary: Several earlier studies have identified significantly higher short-term mortality rates for patients undergoing percutaneous coronary intervention with incomplete revascularization in comparison to patients who received complete revascularization. This study examined the impact of incomplete revascularization on 8-year mortality after coronary stenting for multivessel disease. The results show that the 8-year survival rate was marginally significantly lower for incomplete as compared to complete revascularization after coronary stenting for multivessel disease.
Conclusions: IR may be associated with higher risk of long-term mortality after stenting with BMS in patients with multivessel disease. More prospective studies are needed to further test this association.
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Impact of Drug-Eluting Stents on Distal Vessels
Summary: The comparative effects of BMS and DES on changes in coronary plaque and wall dimensions at the site of treatment are well described. The response of a coronary artery distal to a stent differs according to whether the stent is drug-eluting or bare metal. Distal to a BMS, there is luminal narrowing with progressive negative remodeling. Distal to a DES, there is positive remodeling but increase in plaque volume.
Conclusions: PES use was associated with plaque increase from baseline to 9-month follow-up >5 mm distal to the stent along with positive remodeling, whereas BMS use was associated with negative remodeling and no plaque increase. These vessel responses were consistent in 5-mm long subsegments: 0 to 5 mm versus 5 to 10 mm versus 10 to 15 mm distal to the stent.
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The Impact of Anemia on Long-term Clinical Outcome in Patients Undergoing Revascularization With the Unrestricted Use of Drug-Eluting Stents
Summary: Anemia is frequently encountered among patients with cardiovascular disease. Anemia importantly affects outcome of patients with coronary artery disease undergoing revascularization. Anemia does not seem to influence the type of antithrombotic therapy at the time of hospital discharge. Severe anemia is associated with impaired long-term survival and an increased risk of overall definite and definite or probable stent thrombosis.
Conclusions: Severe anemia is common among patients undergoing PCI with the unrestricted use of DES and adversely affects long-term prognosis, including survival.
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Clinical Outcomes and Treatment After Drug-Eluting Stent Failure: The Absence of Traditional Risk Factors for In-Stent Restenosis
Summary: DES restenosis is not an infrequent clinical problem, particularly when treating complex lesions/patients. The optimal treatment for this condition remains unknown. Recurrence of ISR after DES treatment failure is not infrequent; there is a 12.2% rate of clinically driven revascularization at 1-year follow-up. None of the traditional risk factors for ISR predicts the occurrence of recurrent DES-ISR in this series. Re-DES, VBT, and c-PCI seem to be similarly efficient. Despite the fact that patients treated with VBT were sicker and had more complex disease, they had comparable results to re-DES or balloon angioplasty strategy.
Conclusions: Recurrence of ISR after DES treatment failure is neither infrequent nor benign, and optimal therapy remains unclear and challenging. Given the absence of traditional risk factors for ISR in this population, further research is required to elucidate both the correlates involved in DES ISR and the optimal treatment for this condition.
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Bare Metal Stent Thrombosis and In-Stent Neoatherosclerosis
Summary: Very late stent thrombosis occurs in patients with bare metal stent implantation, although the annual incidence is much lower than that after drug-eluting stent implantation. In-stent neoatherosclerosis with ruptured plaques and thin-cap fibroatheromas has been observed in bare metal stents. Atherosclerotic plaques harvested from patients with very late stent thrombosis and those with acute coronary syndrome unrelated to stent thrombosis were histologically indistinguishable from each other; showing foamy macrophages, cholesterol crystals, and thin fibrous cap. Disruption of neoatherosclerosis inside the stents could be an important underlying mechanism of very late stent thrombosis beyond 3 years after bare metal stent implantation.
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Conclusions: Fragments of atherosclerotic plaque were highly prevalent in patients with VLST beyond 3 years. Disruption of in-stent neoatherosclerosis could play an important role in the pathogenesis of VLST of BMS occurring beyond 3 years after implantation.
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Predictors and Implications of Stent Thrombosis in Non-ST-Segment-Elevation Acute Coronary Syndromes: The ACUITY Trial
Summary: Predictors and clinical correlates of stent thrombosis have been investigated mainly in patients with stable coronary artery disease. There are scant data on the incidence, predictors, and outcomes of stent thrombosis in patients with non-ST-segmentelevation acute coronary syndromes. The present report is the largest study to date to investigate early and late stent thrombosis in patients with moderate and high-risk non-ST-segment-elevation acute coronary syndromes.
Conclusions: Compared with elective stent implantation, ST occurs with increased frequency in the first year after stent implantation in patients with NSTE-ACS, especially within the first 30 days, and is associated with marked increases in cardiac mortality and adverse events. Insulin-treated diabetes, number of diseased vessels, and dynamic ST-segment changes were independent predictors of 1-year ST in NSTE-ACS.
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Stent Comparisons Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the SirolimusEluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial
Summary: First-generation drug-eluting stents releasing sirolimus or paclitaxel from durable polymers have reduced restenosis compared with bare metal stents in a broad spectrum of patients and lesion subsets. Sirolimus-eluting stents (SES) have been shown to be more effective than paclitaxel-eluting stents (PES) in most studies with angiographic follow-up up to 1 year. However, the differential safety profile of SES and PES during long-term followup has not been established. Moreover, the phenomenon of very late stent thrombosis emerged among more complex patients, and long-term data from randomized trials with the unrestricted use of drug-eluting stents are not available. A total of 1012 patients were randomly assigned to SES or PES and followed for up to 5 years as part of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) LATE trial. Initial advantages of SES compared with PES in major adverse cardiac events and target lesion revascularization were partially canceled out by subsequent advantages of PES compared with SES (P for interaction <0.001). Major adverse cardiac events occurred in 19.7% of SES-and 21.4% of PES-treated patients (P=0.39) at 5 years. Similarly, there were no differences in terms of cardiac death, myocardial infarction, target lesion revascularization, and stent thrombosis. Repeat angiography was completed in 43.8% at 5 years. The delayed lumen loss amounted to 0.37±0.73 mm among SES-treated patients and 0.29±59 mm among PES-treated patients (P=0.32).
Conclusions: Long-term follow-up of first-generation drug-eluting stents shows no significant differences in clinical and angiographic outcomes between SES and PES. The continuous increase in late lumen loss in conjunction with the ongoing risk of very late stent thrombosis suggests that vascular healing remains incomplete up to 5 years after implantation of first-generation drug-eluting stents.
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Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV)
Summary: Among drug-eluting stents released to date, the sirolimuseluting stent has demonstrated the least amount of late lumen loss, but its efficacy and safety have not been compared head-to-head with the nextgeneration everolimus-eluting stent. The Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV) trial compared the everolimus-eluting stent with the sirolimus-eluting stent in patients with coronary artery disease. The primary end point was a composite of safety (cardiac death, myocardial infarction, definite stent thrombosis) and efficacy (target vessel revascularization) parameters. A total of 1390 patients were assigned to receive the everolimus-eluting stent and 1384 patients to the sirolimus-eluting stent. At the 9-month follow-up, 4.9% of the patients treated with the everolimus-eluting stent compared with 5.2% of the patients treated with the sirolimus-eluting stent experienced the primary end point (P for noninferiority=0.01). At the 18-month follow-up, this difference remained. The rate of definite stent thrombosis was higher in the sirolimus-eluting group compared with the everolimus-eluting group (0.9% versus 0.2%).
Conclusions:
The everolimus-eluting stent was found to be noninferior to the sirolimus-eluting stent.
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Comparison of Everolimus-Eluting and SirolimusEluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET)
Summary: Several recent randomized trials comparing everolimuseluting stents (EES) and sirolimus-eluting stents (SES) reported similar outcomes. However, only 1 trial was powered for a clinical end point, and no trial was powered for evaluating target-lesion revascularization. Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial is a prospective multicenter randomized, open-label trial comparing EES with SES in Japan. The trial was powered for evaluating noninferiority of EES relative to SES in terms of target-lesion revascularization. From February and July 2010, 3197 patients were randomly assigned to receive either EES (1597 patients) or SES (1600 patients). At 1 year, the primary efficacy end point of target-lesion revascularization occurred in 65 patients (4.3%) in the EES group, and in 76 patients (5.0%) in the SES group, demonstrating noninferiority of EES to SES (P noninferiority <0.0001, and P superiority=0.34). Cumulative incidence of definite stent thrombosis was low and similar between the 2 groups (0.32% versus 0.38%; P=0.77).
Conclusions: One-year clinical and angiographic outcome after EES implantation was noninferior to and not different from that after SES implantation in a stable coronary artery disease population with relatively less complex coronary anatomy. One-year clinical outcome after both EES and SES use was excellent with a low rate of target-lesion revascularization and a very low rate of stent thrombosis. Clinical follow-up will be continued up to 3 years. Future studies comparing different drug-eluting stents should focus more on patients with complex coronary artery disease to discern meaningful differences in safety and efficacy outcomes. 
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Editors' Picks e51 the DES types are less well defined. Although each of the DES has had claims of superior efficacy or safety, direct comparisons have been limited. The analyses from 76 randomized clinical trials with 117 762 patient-years of follow-up showed that DES are highly efficacious at reducing the risk of target-vessel revascularization without causing an increase in any safety outcomes.
Conclusions: DES are highly efficacious at reducing the risk of targetvessel revascularization without an increase in any safety outcomes, including stent thrombosis. However, among the DES types, there were considerable differences, such that EES, SES, and ZES-R were the most efficacious and EES was the safest stent.
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Very Late Coronary Stent Thrombosis of a NewerGeneration Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study
Summary: Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with an increased risk of very late stent thrombosis with an annual incidence of 0.5% to 0.6%. It is unknown whether the risk of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES). A total of 12 339 patients undergoing treatment with either SES, PES, or EES between 2002 and 2009 were followed up for up to 4 years to compare the incidence of stent thrombosis between stent types with particular focus on very late stent thrombosis. The incidence rate of stent thrombosis through 4 years was lower among EES-treated patients (1.4%) compared with patients treated with SES (2.9%; P<0.0001) and PES (4.4%; P<0.0001). The reduction in stent thrombosis was most prominent during the very late time period (>1 year) with a 67% (EES versus SES) and 76% (EES versus PES) risk reduction in favor of EES. The annual incidence rate of very late stent thrombosis amounted to 0.2% in EES, 0.5% with SES, and 0.8% with PES. The lower risk of cardiac death or myocardial infarction with EES compared with PES (hazard ratio, 0.67; 95% confidence interval, 0.58-0.77; P<0.0001) was directly related to the lower risk of stent thrombosis-associated events. Newer-generation EES improve clinical outcome by reducing the risk of stent thrombosis compared with early-generation drug-eluting stents during long-term follow-up. The important reduction of the risk of very late stent thrombosis with the unrestricted use of EES overcomes the principal limitation of early-generation drug-eluting stents and constitutes an important advance in drug-eluting stent safety.
Conclusions: Current treatment with EES is associated with a lower risk of very late stent thrombosis compared with early-generation drug-eluting stents.
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Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus
Summary: Patients with diabetes mellitus are at high risk for major adverse cardiac events after percutaneous coronary intervention. Drugeluting compared with bare metal stents improve event-free survival in diabetic patients by decreasing ischemia-driven repeat revascularization procedures (target lesion revascularization). In large trials, everolimus-eluting stents have been shown to be safer and more effective than paclitaxel-eluting stents; whether this holds equally for diabetic patients has been debated. In the present large-scale study drawn from a pooled patient-level analysis of 4 randomized trials, patients without diabetes mellitus treated with everolimus-eluting stents compared with paclitaxel-eluting stents had significantly reduced 2-year rates of mortality, myocardial infarction, stent thrombosis, and ischemiadriven target lesion revascularization. In contrast, clinical outcomes with the 2 stents were not significantly different in patients with diabetes mellitus. Statistically significant interaction effects were present, suggesting that the difference in the relative effects of these 2 stents is conditioned by the diabetic state. Furthermore, non-insulin-treated diabetic patients had reduced rates of ischemia-driven target lesion revascularization with everolimus-eluting stents, whereas insulintreated patients tended to have reduced rates of ischemia-driven target lesion revascularization with paclitaxel-eluting stents. These data thus demonstrate that the diabetic state, specifically insulin treatment, may substantially affect the clinical outcomes of patients treated with everolimus-eluting stents and paclitaxel-eluting stents. Further studies are required to understand the mechanisms underlying these findings so that more effective therapies can be developed for high-risk patients with diabetes mellitus.
Conclusions:
The authors have identified a substantial interaction between diabetes mellitus and stent type on clinical outcomes after percutaneous coronary intervention. In patients without diabetes mellitus, everolimus-eluting stents compared with paclitaxel-eluting stents resulted in substantial 2-year reductions in death, myocardial infarction, stent thrombosis, and target lesion revascularization, whereas no significant differences in safety or efficacy outcomes were present in diabetic patients. Conclusions: Everolimus-eluting stents were noninferior to sirolimuseluting stents in reducing in-segment late loss and reduced angiographic restenosis at 8 months in patients with diabetes mellitus and coronary artery disease. Therefore, the findings suggested that everolimus-eluting stent implantation is a good option for the diabetic population. Conclusions: In contemporary practice of percutaneous coronary intervention procedures, the unrestricted use of EES and SES showed similar rates of safety and efficacy outcomes with regard to death, MI, sent thrombosis, and TVR. Future longerterm follow-up is needed to better define the relative benefits of these drug-eluting stents. Summary: Numerous randomized clinical trials and registries have demonstrated the short-and long-term efficacy and safety between sirolimus-eluting stents and paclitaxel-eluting stents. There has been some controversy on long-term clinical outcomes between patients treated with sirolimus-eluting stents and paclitaxel-eluting stents. The present analysis presents the largest and longest follow-up data of unselected patients treated with sirolimus-eluting stents and paclitaxel-eluting stents.
The PES was inferior to the SES in the clinical followup of more than 9000 patients' cohort for 5 years, which was mainly driven by the difference in the first year. In the subpopulation of people with diabetes that showed higher MACE than people without diabetes, however, PES was comparable to SES in any clinical outcome for 5 years. Although these 2 stents are not frequently used as before, the data would be useful to expect the long-term clinical course of the current DES.
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Everolimus-Eluting Versus Sirolimus-Eluting Stents: A Meta-Analysis of Randomized Trials
Summary: A large number of randomized, controlled trials showed the superiority of sirolimus-eluting stents (SES; Cypher) compared with first-generation paclitaxel-eluting stents (PES). The second-generation everolimus-eluting stent (EES; Xience V) has clearly been shown superior to PES, but its relative merits against SES have been less extensively assessed. To fill this gap, the authors performed a meta-analysis of randomized, controlled trials comparing EES and SES in patients with coronary artery disease. The authors identified 5 eligible randomized trials comparing EES with SES in 7370 patients. The primary end point was major adverse cardiac events. Conclusions: This meta-analysis did not show significant differences between EES and SES in terms of clinical efficacy and safety. Future studies with longer follow-up are needed to better define the relative merits of these drug-eluting stents.
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Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial: A Randomized Comparison of 3 Drug-Eluting Stents in Diabetic Patients
Summary: Diabetic patients with de novo lesions in native coronary arteries were randomly assigned to be treated with sirolimus-eluting stents (Cypher group; n=76), paclitaxel-eluting stents (Taxus group; n=75), or everolimus-eluting stents (Endeavor group; n=75). The primary end point of the study was a composite of major adverse cardiac events (MACE), including death of any cause, myocardial infarction, and clinically driven target vessel revascularization at 3 years. MACE-free survival was found to be 86.8% in the Cypher group, 82.5% in the Taxus group, and 64.4% in the Endeavor group (P=0.006 by log-rank test). Post hoc analysis showed no significant difference between the Cypher and Taxus groups (adjusted, P=1.0), whereas a higher MACE rate was observed in the Endeavor group as compared with the Cypher group (adjusted, P=0.012) and the Taxus group (adjusted, P=0.075).
Conclusions: The present pilot study suggests that in diabetic patients, the Endeavor stent is associated with a higher 3-year MACE rate when compared with Cypher and Taxus stents. 45 
